Gilead SEC filing confirms FDA warning letter on GMP concerns
This article was originally published in Scrip
Executive Summary
Gilead Sciences has stated in a US Securities and Exchange Commission filing that it has received a warning letter from the FDA concerning good manufacturing practice (GMP) deficiencies at its San Dimas, California, facility. Until the firm is able to correct the outstanding issues, Gilead says that it may be forced to curtail exports of its antifungal treatment AmBisome (amphotericin B).